Class 4

Class 4 Medicines Notification: Rabeprazole sodium 10mg and 20mg gastro-resistant tablets, EL(25)A/01

Bristol Laboratories Limited has informed the MHRA that the Patient Information Leaflet (PIL) in the batches in the table for Rabeprazole sodium 10mg and 20mg gastro-resistant tablets do not contain the most up to date safety information.

DMRC: DMRC 33946703

Company name: Bristol Laboratories Limited

Product descriptions: 

Rabeprazole sodium 10mg gastro-resistant tablets, PLGB 17907/0457 SNOMED Code 36601411000001106

Batch NumberExpiry DatePack SizeFirst Distributed
LC7204710/2025284 September 2023
LC7474402/20262818 October 2023
LC7688805/20262830 September 2024

 

Rabeprazole sodium 20mg gastro-resistant tablets, PLGB 17907/0458 SNOMED Code 36601611000001109

Batch NumberExpiry DatePack SizeFirst Distributed
LC7204512/2025288 March 2023
LC7552605/20262824 August 2023
LC7690608/20262830 September 2024

Brief description of problem:

Bristol Laboratories Limited has informed the MHRA that the Patient Information Leaflet (PIL) in the above specified batches of Rabeprazole sodium 10mg gastro-resistant tablets and Rabeprazole sodium 20mg gastro-resistant tablets do not contain the most up to date safety information. The affected sections of the PIL are summarised in the table below:

Section 2What you need to know before you take Rabeprazole SodiumDo not take Rabeprazole Sodium
Section 2What you need to know before you take Rabeprazole SodiumWarnings & Precautions
Section 2What you need to know before you take Rabeprazole SodiumChildren
Section 2What you need to know before you take Rabeprazole SodiumOther medicines and Rabeprazole Sodium
Section 2What you need to know before you take Rabeprazole SodiumPregnancy and breastfeeding
Section 2What you need to know before you take Rabeprazole SodiumDriving and using machines
Section 3How to take Rabeprazole sodiumTaking the Medicines
Section 3How to take Rabeprazole sodiumIf you forget to take Rabeprazole sodium
Section 4Possible Side EffectsStop taking this medicine
Section 4Possible Side EffectsOther possible side effects Common (affect less than 1 in 1000)
Section 4Possible Side EffectsOther possible side effects (affect less than 1 in 100 people)
Section 4Possible Side EffectsOther possible side effects Rare (may affect up to 1 in 1000 people)
Section 4Possible Side EffectsOther possible side effects (unknown frequency)
Section 4Possible Side EffectsReporting of side effects

Advice to Healthcare Professionals:

The quality of medicine has not been affected, therefore, the affected batches are not being recalled.

Healthcare professionals are advised to ensure that the patients are aware of the updated safety information when dispensing the affected batches of product. Please provide a copy of the updated PIL and remind the patient to read the entire leaflet before taking the medicine. The electronic version of the PIL is up to date and can be accessed via the following links:

Rabeprazole sodium 10mg gastro-resistant tablets

Rabeprazole sodium 20mg gastro-resistant Tablets

Advice to Patients:

The quality of medicine has not been affected, therefore patients do not need to take any action. Patients should continue to take medicines from these batches as prescribed by your healthcare professional.

Patients should be aware that the Patient Information Leaflet (PIL) included in the packs of the above specified batches of medicines does not contain the most up to date safety information. The affected sections of the PIL are included in the table under ‘Brief description of the problem’. The up-to-date version of the Patient Information Leaflet can be accessed via the links below. Please read this before taking the medicine.

Rabeprazole sodium 10mg gastro-resistant tablets

Rabeprazole sodium 20mg gastro-resistant Tablets

If you have any concerns about the information provided with your medicine, please speak with your pharmacy team in the first instance. If you have concerns about a medicine, you may be using, please contact your healthcare professional.

Patients who experience adverse reactions or have any questions about the medication, should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.

Company contacts for further information:

For medical information enquiries please contact at: email: info@bristol-labs.co.uk, or telephone: +44 (0) 1442 200 922

For stock control enquiries please contact at email: notifications@bristol-labs.co.uk, or telephone: +44 (0) 1442 200 922

To access the full recall: Class 4 Medicines Notification: Rabeprazole sodium 10mg and 20mg gastro-resistant tablets, EL(25)A/01